mced

Adela's blood test in development for 20 cancer types, built on reading DNA methylation across the whole genome; no peer-reviewed screening results yet.

GC Genome's blood test from South Korea, launched in 2023 for six cancers, built on a method published with KAIST.

Ajinomoto's Japanese blood test that ranks the risk of several cancers separately from amino acid levels; in a validation of 10,245 people it found 34 cancers.

A methylation blood test for six common cancers announced by AnchorDx of Guangzhou in 2020 at a target cost of about $100; whether it reached the market could not be confirmed.

ClearNote Health's blood test for several cancers, one of the two tests in the US National Cancer Institute's randomised Vanguard study, with no published performance figures yet.

A Chinese blood test that measures physical properties of blood rather than molecules; its developer has since turned to a different business, and the test's status is unclear.

IMBdx's blood test from South Korea, offered at screening centres there, which in a laboratory study detected nine in ten cancers including stage I.

Exact Sciences' multi-cancer blood test, sold since 2025 as a lab test that has not been through FDA approval; it says whether a cancer signal is present but not where, so a positive result leads to scans.

The Johns Hopkins blood test that first showed one draw could find several cancers and point to the organ; its approach passed to Thrive Earlier Detection and then to Exact Sciences, whose Cancerguard test followed.

A German blood test that measures how blood proteins change shape; the only studies are small, run with the inventor, and do not say how often it finds early cancers.

Blood carries fragments of tumour DNA. This roadmap follows the tests that read them, from the first sighting in 1948 to blood tests that now choose a drug, spare chemotherapy, or screen for many cancers at once, and it lists the readouts to watch next.

Led PATHFINDER, the first prospective study of a multi-cancer blood test in practice, and the PROSPECT rectal cancer trial.

A Glasgow company's blood test that shines infrared light through serum to look for cancer; it is sold in the UK for brain tumours, and the multi-cancer version is still in study.

A test in development from Elypta in Sweden that reads sugar molecules in urine and blood rather than DNA, aiming to flag many cancers including some that DNA tests find hard to see.

A research blood test that looks for six digestive-system cancers at once and predicts which organ the signal comes from.

Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.

GRAIL's blood test that looks for a signal from more than 50 cancers at once; an FDA advisory panel voted in its favour in September 2026, but in the NHS-Galleri randomised trial three yearly tests did not reduce the number of cancers found at a late stage.

Singlera and Fudan University's blood test for five digestive-system cancers, which found about eight in ten of them in hospital patients but flagged about one in eighteen people without cancer.

Berry Oncology's blood test for six cancers common in China, launched in 2022; its accuracy figures are the company's own and no peer-reviewed multi-cancer paper was found.

A Mumbai company's blood test that scores one embryonic gene and claims to detect and stage any cancer; the published support is the company's own description and case studies, without accuracy figures.

A methylation blood test for eight cancers from Geneplus-Beijing and Sun Yat-sen University Cancer Center, which found about eight in ten cancers in people already diagnosed; it has not been tested in a screening population.

A Japanese urine test that uses the sense of smell of tiny worms; it is sold directly to the public in Japan, does not say which cancer, and in a real-world analysis about 2 in 100 people with a positive result were found to have cancer (about 12 in 100 after allowing for cancers the follow-up scan can miss).

Natera's blood test in development for several cancers, given FDA Breakthrough Device designation in October 2026 on data from 12 cancer types; no performance figures have been published.

Co-developed CancerSEEK, the blood test that showed multi-cancer early detection is possible, and ran the first prospective screening study of it.

An experimental blood test that reads a handful of proteins, with different panels for men and women, to find many early cancers; so far it has been tried only on a few hundred stored samples.

VolitionRx's blood test that measures DNA packaging released by dying cells; a version is sold for dogs, and the human multi-cancer test is at preprint stage.

SeekIn's low-cost protein blood test for 14 cancers, designed for countries that cannot afford DNA sequencing; it finds about six in ten cancers but flags about one in twelve people without cancer.

An Indian blood test that reads thousands of small molecules in serum; its developer reports about 98% accuracy for 30 cancers, figures that have not been checked independently.

A low-cost blood test from 20/20 BioLabs that measures a panel of protein tumour markers and is sold in the United States as a laboratory test without FDA review.

Burning Rock's methylation blood test from China for five or six cancers, with Breakthrough designations from the US and Chinese regulators but no approval yet.

Singlera's methylation blood test, tested on stored samples from a Chinese cohort, that reported finding cancers up to four years before they were diagnosed; it has not been confirmed in a prospective study.

A German blood test sold through a private health insurance add-on, which claims to signal cancer of any type; its published evidence is small studies and case reports.

Harbinger Health's blood test meant for the weeks between a doctor suspecting cancer and a diagnosis, pointing to where in the body a cancer may be; it is not offered as a screening test for well people.

SeekIn's multi-omic blood test that adds DNA sequencing to its protein test; in published studies it found about six to seven in ten cancers and about four in ten at stage I.

Guardant Health's blood test for ten cancers, offered in the United States as an add-on report to its bowel cancer blood test and chosen by the US National Cancer Institute for its first randomised study of such tests.

Gene Solutions' low-cost blood test from Vietnam; in 9,024 people without symptoms about one in two hundred tested positive and four in ten of those had cancer.

An Amsterdam research test that reads RNA inside blood platelets and detected 18 cancer types in a laboratory study, though it often flagged people with other illnesses.

A urine test in development from TOBY, Inc. that looks for cancer-linked chemicals in urine; it received FDA Breakthrough Device designation in April 2026, and its only performance figures are the company's own.

Genecast's methylation blood test for seven cancers, which found about two in three cancers in a laboratory set; the developers say it still needs a large prospective study.

Datar Cancer Genetics' blood test that looks for clumps of tumour cells, sold privately in the UK; the developer's marketing figures go beyond what its own papers report.